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Abstract
Histone deacetylase (HDAC) inhibitors are a class of promising new
multifunctional anticancer agents. These agents are able to affect multiple
epigenetic changes in aberrant cells. In addition to regulating the gene
expression and transcription via chromatin remodeling, HDAC inhibitors
can also modulate a variety of cellular functions including proliferation,
differentiation, and apoptosis. Vorinostat (SuberAniloHydroxamic Acid,
SAHA), the first HDAC inhibitor approved by FDA, inhibited the metastasis
of various cancer cells. However, SAHA distributes in cancer tissue and
normal tissue in a similar level. It will be ideal to selectively delivery SAHA
into cancer cells. Rapidly growing cancer cells have a great need for
cholesterol to generate new membranes. Increased low-density lipoprotein
(LDL)-uptake by tumor cells has been found. LDL is the major cholesterol
carrier in plasma and its uptake is mediated by the LDL-receptor (LDL-R), a
glycoprotein overexpressed on the surface of cancer cells. Cholesterol can be
used as a delivery agent to enhance anti-cancer drugs penetrating cancer cell
membrane via LDL-R. Degradation of LDL particles by endosomal enzymes
will result in the release of the conjugates to target cancer cells. Herein, we
designed and synthesized SAHA cholesterol conjugate, and tested the anticancer activity of SAHA and its conjugate. The results suggest that cancer
cells uptake more cholesterol SAHA conjugate when the culture medium
does not contain LDL. Based on the information, we will design and
generate artificial LDL containing SAHA cholesterol conjugate to enhance
the drug delivery.

